MiniMed Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MMED in the last 30 days.
See all $MMED insider activity →Medtronic (MDT) is offering shareholders the chance to exchange their shares for MiniMed (MMED) stock, as it divests its final stake in the diabetes tech company. MiniMed went public in March, raising $538 million. Medtronic plans to sell 80.1% of MiniMed's stock at a 7% discount, with shareholders receiving about $107.53 of MiniMed stock for every $100 of Medtronic.
MiniMed (MMED) filed a Form S-4 with the SEC regarding Medtronic's (MDT) offer to exchange up to 80.1% of MiniMed shares for Medtronic shares. Medtronic currently owns 89.86% of MiniMed. If completed, Medtronic will no longer hold an equity stake in MiniMed. The exchange offer is subject to SEC approval and certain conditions.
MiniMed (MMED) reported Q3 revenue growth of 15.8% to $843M, driven by strong sales of its new Flex insulin pump. US pump sales rose over 20% YoY, and international markets saw significant growth. The company raised its full-year revenue growth outlook to 10.5%. However, adjusted EBITDA margin was 9.9%, and free cash flow was negative $90M due to separation costs and other expenses. Management expects future product launches and continued growth.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning MMED (MiniMed Group, Inc.). Coverage has skewed bullish: 2 bullish, 3 neutral, and 1 bearish.
Recent MMED coverage spans earnings, corporate actions and mergers & acquisitions.
MiniMed shares may trade at a discount reflecting the 7% offer price, impacting short‑term price action.
Potential delisting of MiniMed and shift of ownership to Medtronic shareholders.
Positive earnings beat and raised guidance may support short-term upside, but negative free cash flow and high short interest pose downside risk.
Earnings beat and guidance raise likely support further upside.
Guidance raise and product progress could boost price.
AlphAI scores every news story that mentions MMED with an AI model for sentiment and relevance, and aggregates insider trades from MiniMed Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Medtronic (MDT) is offering shareholders the chance to exchange their shares for MiniMed (MMED) stock, as it divests its final stake in the diabetes tech company. MiniMed went public in March, raising $538 million. Medtronic plans to sell 80.1% of MiniMed's stock at a 7% discount, with shareholders receiving about $107.53 of MiniMed stock for every $100 of Medtronic.
2 min readMiniMed (MMED) filed a Form S-4 with the SEC regarding Medtronic's (MDT) offer to exchange up to 80.1% of MiniMed shares for Medtronic shares. Medtronic currently owns 89.86% of MiniMed. If completed, Medtronic will no longer hold an equity stake in MiniMed. The exchange offer is subject to SEC approval and certain conditions.
2 min readMiniMed (MMED) reported Q3 revenue growth of 15.8% to $843M, driven by strong sales of its new Flex insulin pump. US pump sales rose over 20% YoY, and international markets saw significant growth. The company raised its full-year revenue growth outlook to 10.5%. However, adjusted EBITDA margin was 9.9%, and free cash flow was negative $90M due to separation costs and other expenses. Management expects future product launches and continued growth.
3 min readMiniMed Group (MMED) shares rose 19% week-to-date after Q1 2027 results beat revenue expectations. Net sales grew 17% YoY to $843M, with international sales up 18%. The company launched MiniMed Flex insulin pump and raised full-year revenue guidance to 10.5% growth.
2 min readMiniMed Group (MMED) reported strong fiscal 2027 start with US$843M sales, up from US$723M year-over-year. The company cited US growth, international uptake, and regulatory progress. Management raised revenue guidance but noted a cash runway of less than a year. Key milestones include FDA feedback on MiniMed Fit and commercial traction for MiniMed Flex.
2 min readSeveral biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.
2 min readPFE, MMED, and DE stocks hit 52-week highs. PFE rose 0.3% to $29.09 after FDA approvals and strong Q2 results. MMED surged 10% to $22.74 on strong revenue and a price target upgrade. DE gained 3% to $677.89 after launching an AI platform. All three stocks have gained 14-45% YTD.
2 min readMiniMed (MMED) reported Q1 revenue above expectations and raised its full-year sales forecast. The company received CE mark approval for its MiniMed Flex insulin pump, ahead of schedule, and plans a European launch in November. Shares rose over 7% to $21.74 on the news.
2 min readStoneX reiterated a Buy rating and $20.00 price target for MiniMed Group (MMED) ahead of its Q1 earnings. The company expects Q1 2027 revenue of $829M and EBITDA of $117M, aligning with consensus. Analysts forecast 10% organic revenue growth and 16% EBITDA margins for fiscal 2027, driven by product demand and cost efficiencies. MMED trades near its 52-week high at $21.37.
5 min readMiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration • Strong start to fiscal year with net sales of $843 million growing 17% as reported and 16% organic • U.S. net sales growth accelerated to 13%; continu
2 min read
